Istaroxime: a new luso-inotropic agent for heart failure

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Development

Background:

• Acute heart failure syndromes require novel therapeutic agents.
• Istaroxime is a novel luso-inotropic compound targeting cardiac function.
• Understanding istaroxime's safety profile is crucial for its clinical application.

Purpose of the Study:

• To evaluate the safety and efficacy of istaroxime in preclinical models.
• To assess istaroxime's impact on cardiac function and survival rates.
• To determine potential adverse effects of istaroxime administration.

Main Methods:

• Administered istaroxime via 24-hour infusion to dogs with chronic heart failure.
• Administered istaroxime orally to BIO TO.2 cardiomyopathic hamsters for 34 weeks.
• Monitored arrhythmic events, hemodynamic effects in dogs, and mortality in hamsters.

Main Results:

• Istaroxime did not induce or worsen arrhythmias in dogs at tested doses.
• Istaroxime enhanced left ventricular contractility (dP/dtmax) in dogs without altering heart rate or blood pressure.
• A dose of 30 mg/kg istaroxime significantly prolonged survival in cardiomyopathic hamsters by 32%.

Conclusions:

• Istaroxime exhibits a promising safety profile for treating heart failure.
• The compound effectively improves cardiac performance in preclinical models.
• Istaroxime represents a potential new therapeutic option for patients with cardiac dysfunction.